Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants.

Nuytemans K, Maldonado L, Ali A, John-Williams K, Beecham GW, Martin E, Scott WK, Vance JM.

Neurol Genet. 2016 Jan 14;2(1):e44. doi: 10.1212/NXG.0000000000000044.

2.

What can imaging tell us about cognitive impairment and dementia?

Narayanan L, Murray AD.

World J Radiol. 2016 Mar 28;8(3):240-54. doi: 10.4329/wjr.v8.i3.240. Review.

3.

Emerging preclinical pharmacological targets for Parkinson's disease.

More SV, Choi DK.

Oncotarget. 2016 May 17;7(20):29835-63. doi: 10.18632/oncotarget.8104. Review.

4.

Role of apolipoprotein E in neurodegenerative diseases.

Giau VV, Bagyinszky E, An SS, Kim SY.

Neuropsychiatr Dis Treat. 2015 Jul 16;11:1723-37. doi: 10.2147/NDT.S84266. Review.

5.

Apolipoprotein epsilon 4 genotype is associated with less improvement in cognitive function five years after cardiac surgery: a retrospective cohort study.

Bartels K, Li YJ, Li YW, White WD, Laskowitz DT, Kertai MD, Stafford-Smith M, Podgoreanu MV, Newman MF, Mathew JP.

Can J Anaesth. 2015 Jun;62(6):618-26. doi: 10.1007/s12630-015-0337-8.

6.

Aging, neurodegenerative disease, and traumatic brain injury: the role of neuroimaging.

Esopenko C, Levine B.

J Neurotrauma. 2015 Feb 15;32(4):209-20. doi: 10.1089/neu.2014.3506. Review.

7.

Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.

Huang Y, Mahley RW.

Neurobiol Dis. 2014 Dec;72 Pt A:3-12. doi: 10.1016/j.nbd.2014.08.025. Review.

8.

Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ; ICICLE-PD study group., Barker RA.

Brain. 2014 Oct;137(Pt 10):2743-58. doi: 10.1093/brain/awu201.

9.

Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.

Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner J, Dea D.

Neurobiol Aging. 2014 Sep;35 Suppl 2:S3-10. doi: 10.1016/j.neurobiolaging.2014.03.037. Review.

10.

Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson's disease.

Gregório ML, Pinhel MA, Sado CL, Longo GS, Oliveira FN, Amorim GS, Nakazone MA, Florim GM, Mazeti CM, Martins DP, Tognola WA, Brandão AC, Júnior SP, de Godoy MF, Souza DR.

Biomed Res Int. 2013;2013:641515. doi: 10.1155/2013/641515.

11.

CNF1 increases brain energy level, counteracts neuroinflammatory markers and rescues cognitive deficits in a murine model of Alzheimer's disease.

Loizzo S, Rimondini R, Travaglione S, Fabbri A, Guidotti M, Ferri A, Campana G, Fiorentini C.

PLoS One. 2013 May 30;8(5):e65898. doi: 10.1371/journal.pone.0065898. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/8da0f878-fcab-4f65-bad0-c5bdda8181ed.

12.

α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment.

Korff A, Liu C, Ginghina C, Shi M, Zhang J; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2013;36(4):679-88. doi: 10.3233/JAD-130458.

13.

Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Mahley RW, Huang Y.

Neuron. 2012 Dec 6;76(5):871-85. doi: 10.1016/j.neuron.2012.11.020. Review.

14.

Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia.

Fujioka S, Sundal C, Strongosky AJ, Castanedes MC, Rademakers R, Ross OA, Vilariño-Güell C, Farrer MJ, Wszolek ZK, Dickson DW.

Acta Neuropathol. 2013 Mar;125(3):425-38. doi: 10.1007/s00401-012-1059-4.

15.
16.

Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Leduc V, Domenger D, De Beaumont L, Lalonde D, Bélanger-Jasmin S, Poirier J.

Int J Alzheimers Dis. 2011 Apr 5;2011:974361. doi: 10.4061/2011/974361.

17.

ApoE isoform-specific regulation of regeneration in the peripheral nervous system.

Comley LH, Fuller HR, Wishart TM, Mutsaers CA, Thomson D, Wright AK, Ribchester RR, Morris GE, Parson SH, Horsburgh K, Gillingwater TH.

Hum Mol Genet. 2011 Jun 15;20(12):2406-21. doi: 10.1093/hmg/ddr147.

18.

ApoE E4 is a susceptibility factor in amnestic but not aphasic dementias.

Rogalski EJ, Rademaker A, Harrison TM, Helenowski I, Johnson N, Bigio E, Mishra M, Weintraub S, Mesulam MM.

Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):159-63. doi: 10.1097/WAD.0b013e318201f249.

19.

Brain molecular aging, promotion of neurological disease and modulation by sirtuin 5 longevity gene polymorphism.

Glorioso C, Oh S, Douillard GG, Sibille E.

Neurobiol Dis. 2011 Feb;41(2):279-90. doi: 10.1016/j.nbd.2010.09.016.

20.

Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice.

Buttini M, Masliah E, Yu GQ, Palop JJ, Chang S, Bernardo A, Lin C, Wyss-Coray T, Huang Y, Mucke L.

Am J Pathol. 2010 Aug;177(2):563-9. doi: 10.2353/ajpath.2010.090973.

Supplemental Content

Support Center